New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
October 1, 2013
09:17 EDTMYGN, RH, MRK, PSTI, EDG, LXRX, BTN, WAG, AIXGOn The Fly: Pre-market Movers
HIGHER: Merck (MRK), up 3% after announcing restructuring plans, including intent to cut about 20% of workforce by end 2015... Lexicon (LXRX), up 21% after achieving positive clinical trial results for potential diabetes drug... Edgen Group (EDG), up 57% after agreeing to be acquired by Sumitomo Corp. for $12.00 per share... Myriad Genetics (MYGN), up 11% after Piper Jaffray says should be bought on any weakness and stock upgraded at Ladenburg... Ballantyne Strong (BTN), up 6% after acquiring Convergent Media Systems... Pluristem (PSTI), up 5% after PLX cells demonstrate efficacy in preclinical study for GvHD. LOWER: Walgreens (WAG), down 0.5% after Q4 earnings report... Aixtron (AIXG), down 4% after downgrade at Canaccord... Restoration Hardware (RH), down 3% after holder CP Home files to sell about 4M shares.
News For MRK;AIXG;LXRX;RH;WAG;EDG;MYGN;BTN;PSTI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
June 26, 2015
10:00 EDTRHOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
09:04 EDTRHRestoration Hardware upgraded to Buy on RH Modern launch at BB&T
Subscribe for More Information
06:52 EDTRHRestoration Hardware upgraded to Buy from Hold at BB&T
Subscribe for More Information
June 25, 2015
09:52 EDTPSTIPluristem raises $17M in a registered direct offering
Subscribe for More Information
June 24, 2015
09:07 EDTMRKCAR-T cancer drug researchers seen as M&A targets, Bloomberg says
Juno Therapeutics (JUNO), Kite Pharma (KITE) and Bluebird Bio (BLUE) are trading well above their IPO levels as takeovers predictions have spurred interest and share increases for the developers of CAR-T gene therapies, said Bloomberg's "Real M&A" column, quoting Dimo Dimov, a professor at the University of Bath’s School of Management, as having said that companies such as Pfizer (PFE), Merck (MRK), Roche (RHHBY) and AstraZeneca (AZN) are "closely watching" the firms. Cellectis (CLLS), which is working with Pfizer on its own approach to CAR-T therapy, has said it wants to bring its therapy to market and doesn’t anticipate a sale, the report noted. Reference Link
05:30 EDTPSTIPluristem granted Australian patent for 3D cell expansion technology
Pluristem Therapeutics announced that it has been granted an Australian patent titled "Adherent Cells From Placenta Tissue and Use Thereof in Therapy". Patent #2009288781 covers Pluristem's proprietary, three-dimensional method of growing cells from placental or adipose tissue, cells produced by the process, and the use of such cells in the potential treatment of a broad range of conditions. These include peripheral artery disease, other ischemic and cardiovascular diseases, graft-versus-host disease, organ transplantation, cancer, and autoimmune diseases. The patent term will extend until 2027.
June 21, 2015
13:14 EDTMRKMerck shares could return 25%, Barron's says
Subscribe for More Information
June 18, 2015
10:33 EDTRHOptions with decreasing implied volatility
Subscribe for More Information
09:57 EDTRHRestoration Hardware announces pricing of $250M convertible notes offering
Subscribe for More Information
09:33 EDTRHRestoration Hardware trading halted, pending news
Subscribe for More Information
06:09 EDTRHRestoration Hardware implied volatility of 29 at lower end of index mean range
Subscribe for More Information
June 17, 2015
17:00 EDTMRKOncoSec CEO expects 'to be in a better position to attract a strategic partner'
Subscribe for More Information
10:37 EDTRHOptions with decreasing implied volatility
Options with decreasing implied volatility: QIHU BOX RH ADBE NLY
10:00 EDTMRKOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: AbbVie (ABBV) initiated with an Overweight at Piper Jaffray... Arista Networks (ANET) initiated with a Buy at Sterne Agee CRT... Astec (ASTE) initiated with a Buy at Maxim... Bristol-Myers (BMY) initiated with an Underweight at Piper Jaffray... Community Healthcare (CHCT) initiated with an Outperform at Oppenheimer... Eli Lilly (LLY) initiated with an Overweight at Piper Jaffray... Fitbit (FIT) initiated with a Buy ahead of IPO at Dougherty... Hortonworks (HDP) initiated with a Buy at Mizuho... II-VI (IIVI) initiated with a Buy at Benchmark Co.... J Sainsbury (JSAIY) initiated with an Underperform at Credit Suisse... McDermott (MDR) initiated with an Outperform at Cowen... Merck (MRK) initiated with a Neutral at Piper Jaffray... Molina Healthcare (MOH) initiated with a Buy at UBS... Pacific DataVision (PDVW) initiated with a Buy at Canaccord... Pfizer (PFE) initiated with an Overweight at Piper Jaffray... Quest Resource (QRHC) initiated with a Buy at Roth Capital... Regional Management (RM) initiated with a Buy at Janney Capital... Rofin-Sinar (RSTI) initiated with a Buy at Benchmark Co.... Salesforce (CRM) initiated with a Neutral at Exane BNP Paribas... Sprouts Farmers Markets (SFM) initiated with a Neutral at Cleveland Research... Tesco (TSCDY) initiated with an Underperform at Credit Suisse... WM Morrison (MRWSY) initiated with a Neutral at Credit Suisse... WWE (WWE) initiated with a Buy at BTIG... World Acceptance (WRLD) initiated with a Buy at Janney Capital... Zafgen (ZFGN) initiated with a Buy at SunTrust.
08:03 EDTMRKMerck Keytruda granted FDA orphan designation as gastric cancer treatment
The FDA granted Merck, Sharp & Dohme, a subsidiary of Merck, orphan status for Keytruda as a treatment of gastric cancer, including gastroesophageal junction adenocarcinoma. Reference Link
05:36 EDTPSTIPluristem awarded $2.9M grant by Israeli Government
Pluristem Therapeutics announced that its wholly owned subsidiary, Pluristem Ltd., has been awarded approximately $2.9M from the Office of the Chief Scientist of the Israeli Ministry of Economy. The grant will support R&D activities for calendar year 2015.
05:31 EDTMRKMerck initiated with a Neutral at Piper Jaffray
Subscribe for More Information
June 16, 2015
10:11 EDTRHOptions with decreasing implied volatility
Subscribe for More Information
10:07 EDTMRKAlkermes spike attributed to takeover speculation
The spike higher in shares of Alkermes (ALKS) is being attributed by traders to speculation of a takeover. Shares jumped 6% to $61.89 in morning trading. The Ireland based drugmaker focuses on treatments of central nervous system disorders, such as addiction, schizophrenia and depression. The speculative chatter has Merck (MRK) as a potential acquirer of Alkermes. The company’s June 60 and 65 calls are actively trading, according to The Fly's options specialist.
05:58 EDTRHRestoration Hardware implied volatility of 29 at lower end of index mean range
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use